The Toll-Like Receptor Agonist Imiquimod Is Active against Prions

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Oumata, Nassima ^a   Nguyen, Phu hai ^b,h,i   Beringue, Vincent ^c   Soubigou, Flavie ^b,h,i   Pang, Yanhong ^d   Desban, Nathalie ^e   Massacrier, Catherine ^f   Morel, Yannis ^f   Paturel, Carine ^f   Contesse, Marie Astrid ^b,h,i   Bouaziz, Serge ^g   Sanyal, Suparna ^d   Galons, Hervé ^a   Blondel, Marc ^b,h,i   Voisset, Cécile ^b,h,i  

^a Centre National de la Recherche Scientifique   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^c INRA Institut National de la Recherche Agronomique   (France)

^d UPPSALA UNIVERSITY   (Sweden)

^e CNRS   (France)

^f INNATE PHARMA   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h ETABLISSEMENT FRANÇAIS DU SANG   (France)

ⁱ CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BESELNA; CL 075; CL 095; CL 097; GARDIQUIMOD; IMIQUIMOD; IMIQUIMOD DERIVATIVE; LOXORIBINE; RESIQUIMOD; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPRION ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; MOUSE; NONHUMAN; PRION; PROTEIN FOLDING; RIBOSOME; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE; YEAST;

AMINOQUINOLINES; ANIMALS; CELL LINE; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE PEROXIDASE; GUANOSINE; HUMANS; IMIDAZOLES; MEMBRANE GLYCOPROTEINS; MICE; PEPTIDE TERMINATION FACTORS; PRION DISEASES; PRIONS; PROTEIN FOLDING; PRPSC PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84881577196     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072112     Document Type: Article

References (41)

1. Lefrère JJ, Hewitt P, (2009) From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 49: 797-812. doi:10.1111/j.1537-2995.2008.02044.x. PubMed: 19170997.
2. Langevin C, Andréoletti O, Le Dur A, Laude H, Béringue V, (2011) Marked influence of the route of infection on prion strain apparent phenotype in a scrapie transgenic mouse model. Neurobiol Dis 41: 219-225. doi:10.1016/j.nbd.2010.09.010. PubMed: 20875860.
3. Brundin P, Melki R, Kopito R, (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11: 301-307. doi:10.1038/nrm2873. PubMed: 20308987.
4. Frost B, Diamond MI, (2009) The expanding realm of prion phenomena in neurodegenerative disease. Prion 3: 74-77. doi:10.4161/pri.3.2.8754. PubMed: 19448400.
5. Frost B, Diamond MI, (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155-159. PubMed: 20029438.
6. Goedert M, Clavaguera F, Tolnay M, (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 33: 317-325. doi:10.1016/j.tins.2010.04.003. PubMed: 20493564.
7. Miller G, (2009) Neurodegeneration. Could they all be prion diseases? Science 326: 1337-1339. doi:10.1126/science.326.5958.1337. PubMed: 19965731.
8. Soto C, Estrada L, Castilla J, (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31: 150-155. doi:10.1016/j.tibs.2006.01.002. PubMed: 16473510.
9. Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, et al. (2003) Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 21: 1075-1081. doi:10.1038/nbt855. PubMed: 12910243.
10. Bach S, Tribouillard D, Talarek N, Desban N, Gug F, et al. (2006) A yeast-based assay to isolate drugs active against mammalian prions. Methods 39: 72-77. doi:10.1016/j.ymeth.2006.04.005. PubMed: 16750390.
11. Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Béringue V, et al. (2008) Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLOS ONE 3: e2174. doi:10.1371/journal.pone.0002174. PubMed: 18478094.
12. Voisset C, Saupe SJ, Galons H, Blondel M, (2009) Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Infect Disord Drug Targets 9: 31-39. doi:10.2174/1871526510909010031. PubMed: 19200013.
13. Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M, (2008) Tools for the study of ribosome-borne protein folding activity. Biotechnol J 3: 1033-1040. doi:10.1002/biot.200800134. PubMed: 18683165.
14. Couplan E, Aiyar RS, Kucharczyk R, Kabala A, Ezkurdia N, et al. (2011) A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci U S A 108: 11989-11994. doi:10.1073/pnas.1101478108. PubMed: 21715656.
15. Reis SD, Pang Y, Vishnu N, Voisset C, Galons H, et al. (2011) Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie 93: 1047-1054. doi:10.1016/j.biochi.2011.03.002. PubMed: 21396977.
16. Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, et al. (2008) Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLOS ONE 3: e1981. doi:10.1371/journal.pone.0001981. PubMed: 18431471.
17. Klingenstein R, Löber S, Kujala P, Godsave S, Leliveld SR, et al. (2006) Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 98: 748-759. doi:10.1111/j.1471-4159.2006.03889.x. PubMed: 16749906.
18. Schöfer H, (2007) Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. Br J Dermatol 157 (Suppl 2):: 52-55. doi:10.1111/j.1365-2133.2007.08274.x. PubMed: 18067633.
19. Lacarrubba F, Potenza MC, Gurgone S, Micali G, (2011) Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review. J Dermatol Treat 22: 353-358. doi:10.3109/09546634.2010.548503. PubMed: 21781010.
20. Serra-Guillen C, Nagore E, Hueso L, Traves V, Messeguer F, et al. (2012) A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 66: e131-137.
21. Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, et al. (2007) Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 5: 7. doi:10.1186/1479-5876-5-7. PubMed: 17257431.
22. Lee CC, Avalos AM, Ploegh HL, (2012) Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol 12: 168-179. PubMed: 22301850.
23. Archer F, Bachelin C, Andreoletti O, Besnard N, Perrot G, et al. (2004) Cultured peripheral neuroglial cells are highly permissive to sheep prion infection. J Virol 78: 482-490. doi:10.1128/JVI.78.1.482-490.2004. PubMed: 14671128.
24. Vilotte JL, Soulier S, Essalmani R, Stinnakre MG, Vaiman D, et al. (2001) Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp. J Virol 75: 5977-5984. doi:10.1128/JVI.75.13.5977-5984.2001. PubMed: 11390599.
25. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA, (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21: 1-14. doi:10.3109/08923979909016391. PubMed: 10411278.
26. Beringue V, Adjou KT, Lamoury F, Maignien T, Deslys JP, et al. (2000) Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J Virol 74: 5432-5440. doi:10.1128/JVI.74.12.5432-5440.2000. PubMed: 10823847.
27. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, et al. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52: 503-506. doi:10.1002/ana.10336. PubMed: 12325081.
28. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, et al. (2003) Evaluation of quinacrine treatment for prion diseases. J Virol 77: 8462-8469. doi:10.1128/JVI.77.15.8462-8469.2003. PubMed: 12857915.
29. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J, (2007) Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27: 9537-9544. doi:10.1523/JNEUROSCI.1942-07.2007. PubMed: 17804615.
30. Kim Y, de Castro S, Gao ZG, Ijzerman AP, Jacobson KA, (2009). Novel: 2 and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. J Med Chem 52: 2098-2108.
31. Khier S, Deleuze-Masquéfa C, Moarbess G, Gattacceca F, Margout D, et al. (2010) Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma. Eur J Pharm Sci 39: 23-29. doi:10.1016/j.ejps.2009.10.006. PubMed: 19854270.
32. Naddaka V, Saeed S, Montviliski D, Zelikovitch L, Arad O, et al. (2008) Process for preparing Imiquimod. US Patent 7323568, Application number 11/298,711 Bnei-Brak, IL: Assignee Chemagis Ltd.
33. Peinador C, Quintela J, Moreira M, (1997) A Short and Facile Synthesis for Heteromine A. Tetrahedron 53: 8269-8272. doi:10.1016/S0040-4020(97)00492-4.
34. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ, (2008) Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) 233: 968-979. doi:10.3181/0802-RM-58. PubMed: 18480416.
35. Chattopadhyay S, Das B, Dasgupta C, (1996) Reactivation of denatured proteins by 23S ribosomal RNA: role of domain V. Proc Natl Acad Sci U S A 93: 8284-8287. doi:10.1073/pnas.93.16.8284. PubMed: 8710862.
36. Das B, Chattopadhyay S, Bera AK, Dasgupta C, (1996) In vitro protein folding by ribosomes from Escherichia coli, wheat germ and rat liver: the role of the 50S particle and its 23S rRNA. Eur J Biochem 235: 613-621. doi:10.1111/j.1432-1033.1996.00613.x. PubMed: 8654409.
37. Das D, Das A, Samanta D, Ghosh J, Dasgupta S, et al. (2008) Role of the ribosome in protein folding. Biotechnol J 3: 999-1009. doi:10.1002/biot.200800098. PubMed: 18702035.
38. Kudlicki W, Coffman A, Kramer G, Hardesty B, (1997) Ribosomes and ribosomal RNA as chaperones for folding of proteins. Fold Des 2: 101-108. doi:10.1016/S1359-0278(97)00014-X. PubMed: 9135982.
39. Sanyal SC, Bhattacharyya D, Das Gupta C, (2002) The folding of dimeric cytoplasmic malate dehydrogenase. Equilibrium and kinetic studies. Eur J Biochem 269: 3856-3866. doi:10.1046/j.1432-1033.2002.03085.x. PubMed: 12153583.
40. Le Dur A, Béringue V, Andréoletti O, Reine F, Laï TL, et al. (2005) A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes. Proc Natl Acad Sci U S A 102: 16031-16036. doi:10.1073/pnas.0502296102. PubMed: 16239348.
41. Ederth J, Mandava CS, Dasgupta S, Sanyal S, (2009) A single-step method for purification of active His-tagged ribosomes from a genetically engineered Escherichia coli. Nucleic Acids Res 37: e15. PubMed: 19074194.